Posts

Roche drops emugrobart obesity program and returns rights to Chugai

on
Roche is ending obesity development of emugrobart (GYM329), an experimental antibody intended to help preserve muscle while patients lose weight. The decision followed an interim review of the Phase 2 GYMINDA trial. The study tested emugrobart alongside GLP-1/GIP receptor agonists in people with obesity or overweight; the companies concluded clinically meaningful weight loss was unlikely. Chugai says the drug was well tolerated in the study, with no new safety signals. The announcement did not cite a safety concern as the reason for stopping. Roche is returning the licensed rights to Chugai. Chugai is preparing to resume development for spinal muscular atrophy (SMA) and is considering potential licensing partners. This follows Roche’s earlier decision to stop emugrobart development for SMA and facioscapulohumeral muscular dystrophy (FSHD). Sources: Notice Regarding Discontinuation of Development ... Sep 28, 2026 Chugai drops obesity drug development and resumes SMA work...

Mirum’s brelovitug meets Phase 3 primary endpoint in hepatitis delta

on

BARDA offers SCYNEXIS up to $214 million for antifungal SCY-247

on

Could bundled digital and IVD testing speed Alzheimer’s trial referrals?

on

Arvinas doses first patient in ARV-6723 Phase 1/2 trial

on

Biomanufacturing after COVID: keeping emergency readiness commercially viable

on

Kodiak stock surges after two eye-drug candidates match Eylea in Phase 3

on

Merck licenses SciBrunch’s preclinical KRAS G12D drug in deal worth up to $2.13B

on

Merck and Daiichi withdraw lung-cancer drug filing after FDA pushback

on

Adicet reports encouraging early lupus CAR-T data as shares fall

on

ctDNA clearance: a promising early signal, not yet a definitive endpoint

on

Nektar wins $90 million jury award in dispute with Eli Lilly

on

Stipple Bio named to Endpoints 11 for its precision-oncology approach

on